Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $377

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $376 to $377.